AC Immune SA closed at $2.14 on Nov 12, down 5.31%, 42.2% below its 52-week closing high. Volume of 121.8K shares was 0.58× its 20-day average (below normal).
Split-adjusted performance: -10.8% over one month, -23.6% over six months, -36.9% over one year.
Short interest was 2.9M shares at the Oct 30 settlement, down 9.7% from the prior report (3.9% of float, 16.9 days to cover).
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.
What is ACIU's market cap?
$212.77M, based on the Nov 12 close of $2.14.
Does AC Immune SA pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ACIU is sold short?
2.9M shares, 3.9% of float, as of Oct 30, 2026.
About AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
